ABOS News and Press, Acumen Pharmaceuticals Inc. From 04/02/22

Image source: The Motley Fool. Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Q4 2021 Earnings Call Mar 28, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Acumen Pharmaceuticals, Inc. (ABOS) Q4 2021 Earnings Call Tran...

The following slide deck was published by Acumen Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Acumen Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2021 Earnings Conference Call March 28, 2022 4:30 AM ET Company Participants John Woolford - IR, Westwicke Daniel O'Connell - President & CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participan...

Acumen Pharmaceuticals press release (NASDAQ:ABOS): FY GAAP EPS of -$5.02 misses by $1.56. FY Cash and cash  equivalents of $122.16M For further details see: Acumen Pharmaceuticals GAAP EPS of -$5.02 misses by $1.56

Acumen is progressing ACU193, the first monoclonal antibody designed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical testing Currently enrolling INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-as...

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 16, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company w...

Acumen Pharmaceuticals (NASDAQ:ABOS): Q3 GAAP EPS of -$0.10 beats by $0.07. Cash equivalents and marketable securities of $199.96M Press Release For further details see: Acumen Pharmaceuticals EPS beats by $0.07

Acumen’s investigational product candidate, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical trials Enrolled first patients in INTERCEPT-AD, a multi-center, rando...

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company wi...

ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs) Acumen announced dosing of first patient in INTERCEPT-AD in October 2021 and enrollment of patients with ...